1. Home
  2. XNCR vs EVO Comparison

XNCR vs EVO Comparison

Compare XNCR & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xencor Inc.

XNCR

Xencor Inc.

HOLD

Current Price

$11.57

Market Cap

881.9M

Sector

Health Care

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.39

Market Cap

895.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XNCR
EVO
Founded
1997
1993
Country
United States
Germany
Employees
N/A
4766
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
881.9M
895.8M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
XNCR
EVO
Price
$11.57
$2.39
Analyst Decision
Buy
Strong Buy
Analyst Count
10
1
Target Price
$22.33
$7.00
AVG Volume (30 Days)
814.8K
110.9K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
65.36
N/A
EPS
N/A
N/A
Revenue
$125,576,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$11.88
$7.13
P/E Ratio
N/A
N/A
Revenue Growth
13.65
N/A
52 Week Low
$6.92
$2.31
52 Week High
$18.69
$4.80

Technical Indicators

Market Signals
Indicator
XNCR
EVO
Relative Strength Index (RSI) 44.69 32.84
Support Level $10.92 $2.31
Resistance Level $12.87 $3.75
Average True Range (ATR) 0.70 0.08
MACD 0.00 0.02
Stochastic Oscillator 30.65 21.76

Price Performance

Historical Comparison
XNCR
EVO

About XNCR Xencor Inc.

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: